Denali Therapeutics Stock Forecast
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 19.06 -0.52%
DNLI analyst consensus
Consensus (20 analysts)
strong_buy
Avg. price target
$36.06+88.20%
- Strong buy 2
- Buy 17
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Denali Therapeutics (2026-10-08), 19 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $36.06, with a high estimate of $42.00 and a low estimate of $27.00. The average target implies upside of 88.2% from the current price of $19.16.
The spread between the highest and lowest targets is 55.6%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DNLI.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 10% |
| Buy | 17 | 85% |
| Hold | 1 | 5% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $27.00 | +40.92% |
| Average target | $36.06 | +88.20% |
| High target | $42.00 | +119.21% |